Red Bear Angels portfolio company AvantGuard has closed an oversubscribed $1.7 million seed financing round, nearly tripling its original target. The financing drew support from new investors, existing shareholders, and board members, underscoring growing confidence in the company's resistance-proof antimicrobial technology.
Proceeds will support cGMP manufacturing of the monomer and polymer components of AvantGuard's Avantamine platform, an important step toward commercial partnerships and product launch. The platform is designed to provide broad-spectrum, long-lasting protection against bacteria, fungi, and viruses without contributing to antimicrobial resistance, with applications spanning infection prevention, wound care, dermatology, and healthcare environments.
